Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
bone marrow-derived cells
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "bone marrow-derived cells" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-W008634
CAS No.: 56741-95-8
Synonyms: U-54461; U-54461S; PNU-54461
Target:
Research Areas:
Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .
1
Cat. No.: HY-P10424
CAS No.: 2378606-21-2
Target:
Research Areas:
Cat. No.: HY-158650
CAS No.: 2005487-34-1
Target:
Research Areas:
10-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 10-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration. 10-OAHSA reduces LPS (HY-D1056)-induced Tnf-α secretion in bone marrow-derived dendritic cells (BMDCs) .
Cat. No.: HY-173070
CAS No.: 2275612-76-3
Research Areas:
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .
Cat. No.: HY-P11003
CAS No.: 2088834-68-6
Target:
Research Areas:
PTD-N5-1 is an IRF5 inhibitory peptide. PTD-N5-1 blocks the activation of IRF5. PTD-N5-1 inhibits β-glucan-induced IL-12 production in bone marrow-derived dendritic cells pre-stimulated with IFN-γ. PTD-N5-1 reduces the levels of IL-12 and IFN-γ in the kidneys of mice with Candida albicans infection. PTD-N5-1 is applicable to the research of Candida albicans infection .
Cat. No.: HY-N4019
CAS No.: 128988-55-6
Category:
Umbelliferae/Apiaceae Extract Flavonols Plant Flavonoids Monophenols Metabolic Disease Phenols Bupleurum chinensis DC. Extract Disease Research Fields
Target:
Cat. No.: HY-131040
CAS No.: 2068818-02-8
Target:
Research Areas:
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca 2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .
Cat. No.: HY-169819
CAS No.: 882291-37-4
Target:
Research Areas:
Calcium influx inducer compound 634 is a calcium influx inducer. Calcium influx inducer compound 634 (10 µM) enhances the release of extracellular vesicles (EVs) from mouse bone marrow-derived dendritic cells (mBMDCs). Calcium influx inducer compound 634 (10 µM) also increases the levels of CD86 and CD80 on the surface of mBMDCs, an effect that can be blocked by the calcium release-activated calcium channel inhibitor YM-58483 (HY-100831) .
Cat. No.: HY-W615446
CAS No.: 158890-32-5
Research Areas:
GSTO1-IN-3 is a potent GSTO1-1 inhibitor with an IC50 of 0.11 μM, and shows selectivity over GSTO2-2, GSTA1-1 and GSTP1-1 (IC50 > 100 μM). GSTO1-IN-3 enhances the cytotoxicity of Cisplatin (HY-17394) against human breast cancer cells. GSTO1-IN-3 inhibits IL-1β release in mouse bone marrow-derived macrophage (BMDM) cells. GSTO1-IN-3 attenuates inflammation in mice. GSTO1-IN-3 can be used for breast cancer and inflammation research .
Cat. No.: HY-168137
Target:
Research Areas:
NOD2 agonist 2 (compound 23) enhanced the antigen presentation of mouse bone marrow-derived dendritic cells (BMDCs), highlighting its potential as a vaccine adjuvant.
Cat. No.: HY-111077
CAS No.: 933768-63-9
Research Areas:
INCB16562 is an orally active and selective inhibitor against JAK1/2 markedly selective over JAK3. INCB16562 potently inhibits interleukin-6 (IL-6)-induced phosphorylation of STAT3. Additionally, INCB16562 inhibits the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6–induced growth of primary bone marrow-derived plasma cells. INCB16562 antagonizes the growth of myeloma xenografts in mice with antitumor activity. INCB16562 is promising for research of multiple myeloma .
Cat. No.: HY-160850
CAS No.: 384835-48-7
Target:
Research Areas:
C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) is a specific type of long-chain molecule found in murine skin . C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 µM. C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .
Cat. No.: HY-152021S
CAS No.: 2692624-25-0
Target:
Research Areas:
C18 Ceramide-1-phosphate (d18:1/18:0)-d3 is the deuterium labeled C18 Ceramide-1-phosphate (d18:1/18:0) (HY-160850). C18 Ceramide-1-phosphate (d18:1/18:0) is a specific type of long-chain molecule found in murine skin. C18 Ceramide-1-phosphate (d18:1/18:0) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 μM. C18 Ceramide-1-phosphate (d18:1/18:0)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .
Cat. No.: HY-171239
CAS No.: 656831-19-5
Target:
Research Areas:
Ste2Cys is a diacylglycerol cysteine-type immunologic adjuvant lipid molecule. Ste2Cys can bind to TLR2 and activate NF-κB signaling pathway. Ste2Cy can upregulate the expression of MHC II class molecules on the surface of mouse bone marrow-derived D1 dendritic cells. Ste2Cys can be used for research of the development of immunologic vaccines .
Cat. No.: HY-182757
CAS No.: 2812381-74-9
Research Areas:
Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
Cat. No.: HY-P11003A
Target:
Research Areas:
PTD-N5-1 acetate is an IRF5 inhibitory peptide. PTD-N5-1 acetate blocks the activation of IRF5. PTD-N5-1 acetate inhibits β-glucan-induced IL-12 production in bone marrow-derived dendritic cells pre-stimulated with IFN-γ. PTD-N5-1 acetate reduces the levels of IL-12 and IFN-γ in the kidneys of mice with Candida albicans infection. PTD-N5-1 acetate is applicable to the research of Candida albicans infection .
Cat. No.: HY-W018643R
CAS No.: 2309-07-1
Synonyms: Methyl ferulate (Standard)
Category:
Plant Monophenols Stemona tuberosa Lour. Extract Simple Phenylpropanols Phenols Phenylpropanoids Stemonaceae Extract
Target:
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
